18F-AlF-NOTA-octreotide PET/CT 与 68Ga-DOTATATE PET/CT 在神经内分泌肿瘤显像中的对比评估
结果显示两者图像质量相似,18F-OC 在唾液腺和肝脏摄取显著更低,检出更多病灶,肝及淋巴结病灶的肿瘤/肝脏比值更高(p=0.02)。
要点
- 18F-OC 在唾液腺和肝脏的摄取显著低于 68Ga-DOTATATE。
- 18F-OC 检出的病灶数量多于 68Ga-DOTATATE。
- 肝脏及淋巴结病灶的肿瘤/肝脏比值 18F-OC 更高(p=0.02)。
核心结论
- 18F-OC 相比 68Ga-DOTATATE 具有相似图像质量和满意的 NEN 病灶检出率,尤其因肝脏低背景摄取而表现更优,是有前景的临床替代选择。
主要发现
- 在大多数器官中,68Ga-DOTATATE 与 18F-OC 的生物分布无显著差异。
- 18F-OC 在唾液腺和肝脏的摄取显著低于 68Ga-DOTATATE。
- 18F-OC 检出的病灶数量多于 68Ga-DOTATATE。
- 大多数患者中 18F-OC 的肿瘤摄取更高,但差异相对 68Ga-DOTATATE 无统计学意义。
- 大多数患者中 18F-OC 的肿瘤/肝脏比值更高,包括肝脏病灶(p=0.02)和淋巴结病灶(p=0.02)。
关键数值与推荐
- 肝脏病灶肿瘤/肝脏比值比较 p=0.02。
- 淋巴结病灶肿瘤/肝脏比值比较 p=0.02。
临床怎么用
- 18F-OC PET/CT 可作为 68Ga-DOTATATE PET/CT 的临床替代方案用于神经内分泌肿瘤显像,尤其适用于关注肝脏病灶评估的场景。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the diagnostic efficacy of 18F-AlF-NOTA-octreotide (18F-OC) PET/CT compared with that of 68Ga-DOTATATE PET/CT. MATERIALS AND METHODS: Twenty patients (mean age: 52.65 years, range: 24-70 years) with biopsy-proven neuroendocrine neoplasms (NENs) were enrolled in this prospective study. We compared the biodistribution profiles in normal organs based on the maximum standard uptake value (SUVmax) and mean standard uptake value (SUVmean), and uptake in NEN lesions by measuring the SUVmax on 18F-OC and 68Ga-DOTATATE PET/CT images. The tumor-to-liver ratio (TLR) and tumor-to-spleen ratio were calculated by dividing the SUVmax of different tumor lesions by the SUVmean of the liver and spleen, respectively. The Wilcoxon signed-rank test was used to compare nonparametric data. Data were expressed as the median (interquartile range). RESULTS: In most organs, there were no significant differences in the biodistribution of 68Ga-DOTATATE and 18F-OC. 18F-OC had significantly lower uptake in the salivary glands and liver than 68Ga-DOTATATE. 18F-OC detected more lesions than 68Ga-DOTATATE. The uptake of 18F-OC in the tumors was higher in most patients, but the difference was not statistically significant relative to that of 68Ga-DOTATATE. However, the TLRs of 18F-OC were higher in most patients, including for lesions in the liver (p = 0.02) and lymph nodes (p = 0.02). CONCLUSION: Relative to 68Ga-DOTATATE, 18F-OC possesses favorable characteristics with similar image quality and satisfactory NEN lesion detection rates, especially in the liver due to its low background uptake. 18F-OC therefore offers a promising clinical alternative for 68Ga-DOTATATE.
引用
- Hou J, Long T, He Z, et al. Evaluation of 18F-AlF-NOTA-octreotide for imaging neuroendocrine neoplasms: comparison with 68Ga-DOTATATE PET/CT. EJNMMI Res. 2021. PMID: 34106351. doi:10.1186/s13550-021-00797-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。